DE60029314T2
(de)
*
|
1999-03-24 |
2007-07-12 |
Exiqon A/S |
Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
CA2402319A1
(en)
|
2000-03-14 |
2001-09-20 |
Active Motif |
Oligonucleotide analogues, methods of synthesis and methods of use
|
US6962906B2
(en)
|
2000-03-14 |
2005-11-08 |
Active Motif |
Oligonucleotide analogues, methods of synthesis and methods of use
|
US6936467B2
(en)
|
2000-03-27 |
2005-08-30 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
AP2002002638A0
(en)
|
2000-03-27 |
2002-09-30 |
Univ Delaware |
Targeted chromosomal genomic alternations with modified single stranded oligonucleotides.
|
EP1414840A4
(de)
|
2001-03-27 |
2005-04-13 |
Univ Delaware |
Genomics-anwendungen für modifizierte oligonukleotide
|
EP1397373B1
(de)
*
|
2001-06-07 |
2005-02-16 |
Santaris Pharma A/S |
Verbesserte synthesen von allofuranose
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
WO2003020902A2
(en)
*
|
2001-08-31 |
2003-03-13 |
Datascope Investment Corp. |
Methods for blocking nonspecific hybridizations of nucleic acid sequences
|
AU2002334307A1
(en)
|
2001-09-04 |
2003-03-18 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
EP1446503A2
(de)
|
2001-09-27 |
2004-08-18 |
University Of Delaware |
Zusammensetzung und verfahren zur verbesserung der oligonukleotidgesteuerten veränderung von nukleinsäuresequenzen
|
US7468244B2
(en)
|
2001-09-27 |
2008-12-23 |
University Of Delaware |
Polymorphism detection and separation
|
WO2003039523A2
(en)
*
|
2001-11-05 |
2003-05-15 |
Exiqon A/S |
OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
|
JP2005518817A
(ja)
|
2002-03-07 |
2005-06-30 |
ユニバーシティー、オブ、デラウェア |
ヒストン・デアセチラーゼ・インヒビタ、ラムダファージベータ蛋白、またはヒドロキシウレアを含む組成物を使用してオリゴヌクレオチド媒介性核酸配列改変を高める方法、組成物およびキット
|
CA2480311C
(en)
|
2002-04-05 |
2015-01-27 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of hif-1alpha expression
|
US7005265B1
(en)
|
2002-06-20 |
2006-02-28 |
Wenhong Fan |
Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
|
DE60327775D1
(de)
*
|
2002-06-24 |
2009-07-09 |
Exiqon As |
Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
DK3222722T3
(da)
|
2002-11-18 |
2019-06-17 |
Roche Innovation Ct Copenhagen As |
Antisense-design
|
AU2013201786B2
(en)
*
|
2002-11-18 |
2015-04-02 |
Roche Innovation Center Copenhagen A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
PT1592793E
(pt)
|
2003-02-10 |
2009-09-30 |
Santaris Pharma As |
Compostos oligoméricos para a modulação da expressão de survivina
|
US8399196B2
(en)
|
2003-02-21 |
2013-03-19 |
Geneform Technologies Limited |
Nucleic acid sequencing methods, kits and reagents
|
DE602004023279D1
(de)
|
2003-03-21 |
2009-11-05 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
DK1639130T3
(da)
|
2003-06-20 |
2012-07-09 |
Exiqon As |
Prober, biblioteker og kits til analyse af blandinger af nukleinsyrer og metoder til opbygning af disse
|
ATE467679T1
(de)
*
|
2003-12-23 |
2010-05-15 |
Santaris Pharma As |
Oligomere verbindungen zur modulation von bcl-2
|
US8192937B2
(en)
|
2004-04-07 |
2012-06-05 |
Exiqon A/S |
Methods for quantification of microRNAs and small interfering RNAs
|
EP2290074B1
(de)
|
2004-05-28 |
2014-12-17 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen mit MicroRNA
|
DE102004034343B4
(de)
*
|
2004-07-10 |
2007-08-30 |
Olfert Landt |
Verfahren zum Nachweis von Spuren genomischer Varianten mittels Nukleinsäure-Amplifikationsreaktionen
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
DE602005022768D1
(de)
|
2004-11-09 |
2010-09-16 |
Santaris Pharma As |
Wirksame lna-oligonukleotide zur inhibierung von hif-1a
|
EP1824975B9
(de)
|
2004-11-09 |
2011-04-20 |
Santaris Pharma A/S |
Lna-oligonukleotide und krebsbehandlung
|
EP2287303B1
(de)
|
2004-11-12 |
2014-07-02 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
|
EP1959012A3
(de)
|
2004-12-29 |
2009-12-30 |
Exiqon A/S |
Neuartige Oligonukleotid-Zusammensetzungen und Probensequenzen für die Erkennung und Analyse von Mikro-RNAs und ihre Ziel-MRNAs
|
NZ564146A
(en)
*
|
2005-05-25 |
2011-02-25 |
Tina Holding Aps |
Stable and selective formation of Hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (TINA) and process for the preparation of TINA
|
EP3000480A1
(de)
|
2005-12-01 |
2016-03-30 |
ProNAi Therapeutics, Inc. |
Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
|
WO2007073149A1
(en)
|
2005-12-22 |
2007-06-28 |
Keygene N.V. |
Alternative nucleotides for improved targeted nucleotide exchange
|
AU2007229161B2
(en)
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
MY162210A
(en)
|
2006-04-03 |
2017-05-31 |
Roche Innovation Ct Copenhagen As |
Pharmaceutical composition
|
ES2715625T3
(es)
|
2006-04-03 |
2019-06-05 |
Roche Innovation Ct Copenhagen As |
Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
|
EP2090665A2
(de)
|
2006-10-20 |
2009-08-19 |
Exiqon A/S |
Neue humane MikroRNAs im Zusammenhang mit Krebs
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
WO2008086807A2
(en)
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
WO2008113830A1
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
US8999634B2
(en)
|
2007-04-27 |
2015-04-07 |
Quest Diagnostics Investments Incorporated |
Nucleic acid detection combining amplification with fragmentation
|
AU2008262391A1
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
US8299237B2
(en)
|
2007-08-30 |
2012-10-30 |
Hadasit Medical Research Services & Development Ltd. |
Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
|
EP2198050A1
(de)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
|
KR101889518B1
(ko)
|
2007-10-04 |
2018-08-17 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
마이크로MIRs
|
EP3561494B1
(de)
|
2007-12-06 |
2022-03-02 |
Genalyte, Inc. |
VERFAHREN ZUM IDENTIFIZIEREN EINER SEQUENZ VON NUKLEOTIDEN IN EINER UNBEKANNTEN SPEZIES VON NUKLEINSÄURE
UND VORRICHTUNG ZUR DURCHFÜHRUNG DES VERFAHRENS
|
US9879222B2
(en)
|
2007-12-14 |
2018-01-30 |
Mofa Group Llc |
Gender-specific separation of sperm cells and embryos
|
CA2717792A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
EP2315832B1
(de)
|
2008-08-01 |
2015-04-08 |
Roche Innovation Center Copenhagen A/S |
Micro-rna-vermittelte modulation koloniestimulierender faktoren
|
EP2347247B1
(de)
|
2008-10-27 |
2019-06-26 |
Genalyte, Inc. |
Auf optischer sondierung und optischem abtasten basierende biosensoren
|
CN102257147A
(zh)
|
2008-12-22 |
2011-11-23 |
凯津公司 |
在植物原生质体中使用双链rna提高靶基因改变的效率
|
EP2421970B1
(de)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmazeutische zusammensetzungen zur behandlung von nicht auf interferon ansprechende hcv-patienten
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
WO2011032034A2
(en)
|
2009-09-10 |
2011-03-17 |
University Of Idaho |
Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
EP2563935B1
(de)
|
2010-04-30 |
2014-04-16 |
Exiqon A/S |
In-situ-hybridisierungsverfahren und puffer
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
EP3266881B1
(de)
|
2010-11-05 |
2019-12-25 |
Genalyte, Inc. |
Systeme zur optischen analytdetektion und verfahren zur verwendung
|
EP2857512B1
(de)
|
2010-12-02 |
2016-06-29 |
Keygene N.V. |
Gezielte Änderung von DNA
|
AU2011337324B2
(en)
|
2010-12-02 |
2015-11-26 |
Keygene N.V. |
Targeted alteration of DNA with oligonucleotides
|
CA2842103A1
(en)
|
2011-07-19 |
2013-01-24 |
University Of Idaho |
Embodiments of a probe and method for targeting nucleic acids
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
AP2014007796A0
(en)
*
|
2011-12-22 |
2014-07-31 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
WO2013138251A1
(en)
|
2012-03-12 |
2013-09-19 |
The Board Of Trustes Of The University Of Illinois |
Optical analyte detection systems with magnetic enhancement and methods of use
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
CA2890725A1
(en)
|
2012-11-05 |
2014-05-08 |
Pronai Therapeutics, Inc. |
Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
|
EP2943570B1
(de)
|
2013-01-14 |
2018-01-03 |
Pierfrancesco Tassone |
Inhibitoren von mirnas 221 und 222 zur antitumorwirkung bei multiplem myelom
|
US10086093B2
(en)
|
2013-02-28 |
2018-10-02 |
The General Hospital Corporation |
miRNA profiling compositions and methods of use
|
US9983206B2
(en)
|
2013-03-15 |
2018-05-29 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for enhancing immunoassays
|
PE20160158A1
(es)
|
2013-06-27 |
2016-03-18 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en pcsk9
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
WO2015118407A2
(en)
|
2014-01-29 |
2015-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
WO2016027162A2
(en)
|
2014-08-19 |
2016-02-25 |
Tataa Biocenter Ab |
Methods and compositions for nucleic acid detection
|
KR20170058979A
(ko)
|
2014-09-18 |
2017-05-29 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
헌팅턴병 일배체형에 대한 대립 유전자-특이적 치료
|
SG11201702682PA
(en)
|
2014-10-03 |
2017-04-27 |
Cold Spring Harbor Lab |
Targeted augmentation of nuclear gene output
|
DK3341479T3
(da)
*
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
CA3000971A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JP7049248B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
常染色体優性精神遅滞-5とドラベ症候群の処置のためのアンチセンスオリゴマー
|
EP3494219A1
(de)
|
2016-08-03 |
2019-06-12 |
Aalborg Universitet |
Zur hemmung von immun-checkpoint-proteinen designte antisense-oligonukleotide (aso)
|
WO2018181428A1
(ja)
|
2017-03-29 |
2018-10-04 |
塩野義製薬株式会社 |
核酸医薬及び多分岐脂質の複合体
|
AU2018322319B2
(en)
|
2017-08-25 |
2021-08-05 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
US11261445B2
(en)
|
2017-10-17 |
2022-03-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combination treatment for cystic fibrosis
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021020412A1
(ja)
|
2019-07-30 |
2021-02-04 |
塩野義製薬株式会社 |
Murf1を標的とする核酸医薬
|
IT201900017234A1
(it)
|
2019-09-25 |
2021-03-25 |
Int Centre For Genetic Engineering And Biotechnology |
Anti-miRNA per il trattamento del leiomioma
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
US20230287410A1
(en)
|
2020-05-11 |
2023-09-14 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
EP4179091A1
(de)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Verfahren und zusammensetzungen zur behandlung von epilepsie
|
AU2022219031A1
(en)
|
2021-02-12 |
2023-09-07 |
Merand Pharmaceuticals, Inc. |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
JP2024510665A
(ja)
|
2021-03-26 |
2024-03-08 |
ニューミルナ セラピューティクス エーピーエス |
マイクロRNA-27b阻害剤
|
WO2022200632A1
(en)
|
2021-03-26 |
2022-09-29 |
Neumirna Therapeutics Aps |
Microrna-134 inhibitors
|
JP2024522272A
(ja)
|
2021-06-04 |
2024-06-13 |
ニューミルナ セラピューティクス エーピーエス |
アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
|
KR20240046879A
(ko)
|
2021-08-17 |
2024-04-11 |
한국과학기술원 |
Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도
|
CA3228833A1
(en)
|
2021-08-19 |
2023-02-23 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
WO2023092102A1
(en)
|
2021-11-19 |
2023-05-25 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
US20240002857A1
(en)
|
2022-05-09 |
2024-01-04 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
US20240052348A1
(en)
|
2022-08-05 |
2024-02-15 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
EP4332239A1
(de)
|
2022-08-30 |
2024-03-06 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
|
WO2024081954A2
(en)
|
2022-10-14 |
2024-04-18 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|